# Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL

> **NCT05050630** · PHASE2 · UNKNOWN · sponsor: **Affiliated Hospital to Academy of Military Medical Sciences** · enrollment: 73 (estimated)

## Conditions studied

- Age Range ≥16 Years, Gender Unlimited
- Histopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma
- Received Prior First-line Chemotherapy for DLBCL or HGBL, Failed to Reach CR for Four Cycles, or Relapsed
- At Least One Positive Lesion According to the 2014 Lugano Criteria for Hodgkin's and Non-Hodgkin's Lymphoma
- ECOG Physical Status Score is 0-3
- The Researchers Judged That Life Expectancy Was at Least Three Months
- Understand and Voluntarily Sign Written Informed Consent

## Interventions

- **DRUG:** TR2-ICE

## Key facts

- **NCT ID:** NCT05050630
- **Lead sponsor:** Affiliated Hospital to Academy of Military Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-01
- **Primary completion:** 2022-07-30
- **Final completion:** 2023-07-30
- **Target enrollment:** 73 (ESTIMATED)
- **Last updated:** 2021-09-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05050630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05050630, "Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05050630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*